Financiere des Professionnels Fonds d investissement inc. Takes $478,000 Position in CVS Health Corporation $CVS

Financiere des Professionnels Fonds d investissement inc. purchased a new stake in shares of CVS Health Corporation (NYSE:CVS) during the 1st quarter, Holdings Channel reports. The fund purchased 6,657 shares of the pharmacy operator’s stock, valued at approximately $478,000.

A number of other institutional investors have also added to or reduced their stakes in the stock. Sei Investments Co. grew its stake in shares of CVS Health by 17.4% during the second quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator’s stock worth $62,474,000 after buying an additional 134,535 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of CVS Health by 1.2% during the second quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator’s stock worth $77,353,000 after buying an additional 13,329 shares in the last quarter. Treasurer of the State of North Carolina lifted its stake in shares of CVS Health by 1.3% in the 2nd quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator’s stock valued at $40,358,000 after acquiring an additional 7,588 shares during the last quarter. HUB Investment Partners LLC boosted its holdings in shares of CVS Health by 25.0% during the 2nd quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator’s stock valued at $1,039,000 after acquiring an additional 3,011 shares in the last quarter. Finally, Alliancebernstein L.P. grew its position in CVS Health by 8.0% during the 2nd quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator’s stock worth $111,017,000 after acquiring an additional 119,439 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Larry Robbins sold 1,983,538 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the transaction, the director owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. The trade was a 24.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 3,441,551 shares of company stock worth $323,703,977 in the last 90 days. Corporate insiders own 0.85% of the company’s stock.

CVS Health Trading Up 0.8%

NYSE CVS opened at $107.36 on Friday. The business’s 50-day moving average price is $98.97 and its two-hundred day moving average price is $85.13. CVS Health Corporation has a 12 month low of $58.50 and a 12 month high of $108.97. The firm has a market capitalization of $136.99 billion, a PE ratio of 47.30, a price-to-earnings-growth ratio of 1.04 and a beta of 0.61. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. The company had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm’s revenue was up 6.2% compared to the same quarter last year. During the same period last year, the company earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, analysts expect that CVS Health Corporation will post 7.46 EPS for the current year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd will be issued a dividend of $0.665 per share. The ex-dividend date is Thursday, July 23rd. This represents a $2.66 annualized dividend and a yield of 2.5%. CVS Health’s dividend payout ratio (DPR) is presently 117.18%.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS opened its first pharmacy-focused location in Houston and plans to roll out nearly 20 similar sites, signaling an effort to expand access to in-person pharmacy care and strengthen its retail footprint. CVS Pharmacy® celebrates opening of first pharmacy-focused location in Houston
• Positive Sentiment: Management reiterated a constructive stance on GLP-1 drugs and pharmacy economics, with CEO comments highlighting that insurers may eventually cover weight-loss drugs more broadly once prices fall, reinforcing CVS’s role in cost management and pharmacy benefit services. CVS Health CEO David Joyner warns private insurers won’t cover GLP-1s for weight loss until drug prices drop
• Positive Sentiment: CVS also floated cost-saving solutions and a settlement in Georgia that could reduce prescription costs for some patients, which may improve public perception and support demand for its pharmacy services. New CVS settlement could lower prescription costs for some Georgians
• Neutral Sentiment: Coverage around CVS education benefits and talent development highlights workforce stability, but it is unlikely to have an immediate impact on the stock. At CVS, education benefits strengthen talent pipelines
• Neutral Sentiment: Broader analyst and media discussion of CVS’s dividend and GLP-1 strategy has helped reinforce the investment case, but this appears more supportive than a near-term catalyst. How Investors May Respond To CVS (CVS) Dividend Move And GLP‑1 Strategy Across Its Health Platform

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. DA Davidson increased their target price on CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Deutsche Bank Aktiengesellschaft boosted their price target on CVS Health from $88.00 to $92.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. HSBC reaffirmed a “hold” rating and issued a $103.00 price objective on shares of CVS Health in a research note on Monday, July 6th. Wall Street Zen downgraded shares of CVS Health from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. boosted their target price on shares of CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Twenty-one research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and an average target price of $105.38.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.